Remove news tags opioids
article thumbnail

TGA – Australia: Independent Expert Panel on MDMA and psilocybin – Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions

Cannabis Law Report

Professor Mark Connor is a molecular pharmacologist with expertise in analgesics and psychoactive drugs, particularly cannabinoids and opioids, with extensive research experience in the USA, UK, and Australia. We had some great news last week! Tags: medicines scheduling. Panel Members. Professor Mark Connor. URL: [link].

article thumbnail

These Are The Best CBD Oil Pills & Soft Gels To Help You Stay Calm

Miss Marijuana

Tag a friend in the comments below and be entered to win a box for yourself and a box for your friend! It’s easy to worry given the recent news cycle. Charlot Martin-Amadi is a writer who focuses on cannabis news and culture. . Our picks for CBD oil pills and soft gels. Foria Wellness Basics Capsules. PlusCBD Oil Capsules.

Oil 86
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

These Are The Best CBD Oil Pills & Soft Gels To Help You Stay Calm

Miss Marijuana

Tag a friend in the comments below and be entered to win a box for yourself and a box for your friend! It’s easy to worry given the recent news cycle. Charlot Martin-Amadi is a writer who focuses on cannabis news and culture. . Our picks for CBD oil pills and soft gels. Foria Wellness Basics Capsules. PlusCBD Oil Softgels.

Oil 52
article thumbnail

FDA Experts Weigh In On Incannex’s CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder – Incannex Healthcare (NASDAQ:IXHL)

Medical Marijuana Program Connection

IXHL, a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for the treatment of opioid use disorder (OUD). A number of FDA representatives shared insights on.